TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05779774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WayToServe Plus In-service Component
Description: Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WayToServe Training Only
Description: Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
Study: NCT06125470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uptake of quality Reproductive health and Family planning products, information and Services
Description: Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH
Description: Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Engagement
Description: Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renovation and Refurbishment of selected healthcare facilities
Description: Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Data for Effective Decision-making
Description: Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procurement of FP/SRH medical supplies and equipment
Description: Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
Study: NCT05425316

Intervention type: BEHAVIORAL
Intervention: Home Recordings
Description: If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.

Intervention type: BEHAVIORAL
Intervention: Home Recordings
Description: If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.

Intervention type: BEHAVIORAL
Intervention: In-patient Recordings
Description: If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.

Intervention type: BEHAVIORAL
Intervention: Same-Day Study Visit - Regular Appointment
Description: Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.

Intervention type: BEHAVIORAL
Intervention: Same-Day Study Visit - Regular Appointment
Description: Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.

Intervention type: BEHAVIORAL
Intervention: Same-Day Study Visit - Procedure
Description: Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.

Intervention type: BEHAVIORAL
Intervention: Phone Call Follow-up Visits
Description: Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
Study: NCT04857229

Intervention type: DEVICE
Intervention: Histolog Scanner
Description: Confocal Microscope
Study: NCT04052581

Intervention type: PROCEDURE
Intervention: POEM-TIF
Description: Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
Study: NCT04750460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
Study: NCT05701930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: symptom management
Description: pecha kucha training
Study: NCT04857125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient interventions
Description: The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staff education
Description: Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
Study: NCT05928481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based postpartum bleeding management training
Description: Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
Study: NCT06340139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment with Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental treatment
Description: 1 being a fixation point and phase 2 including head and eye movements
Study: NCT03983564

Intervention type: OTHER
Intervention: Cutoff Validation
Description: We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
Study: NCT06491524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone <2cm
Description: Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
Study: NCT06043297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5MG
Description: Each film-coated tablet contains 5 mg apixaban
Study: NCT05841316

Intervention type: DRUG
Intervention: Sugammadex
Description: During the surgery, the desired level of neuromuscular block will be deep and followed by post-tetanic-count (PTC) of 1 to 3 in every 5 minutes. 0.3-1mg/kg/h rocuronium will be infused to ensure PTC of 1 to 3.~At the end of the surgery, 0,6 mg sugammadex will be given as a bolus in the first patient of the study. The duration between the completion of sugammadex injection and the first measurement of Train-of-four ratio (TOFR) of 0.4 will be recorded.~If the TOFR is achieved to 0.4 after sugammadex bolus of 0,6 mg/kg in 5 minutes, the result of reversal will be evaluated as positive. The consecutive patient will be given the same or decreased dose of sugammadex by 0,2 mg/kg according to the randomisation scheme.~If the patient fails to recover from deep neuromuscular block to superficial block in 5 minutes after a given dose of sugammadex, the consecutive patient will be administered increased dose of sugammadex by 0,2 mg/kg.
Study: NCT04786080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Positive
Description: Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~1. structured advice, support and tips for parents~2. facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~3. access to carefully selected high-quality, evidence-based online parenting resources.
Study: NCT05267236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention #1: Treatment Group Receiving On-Demand TYRO Services
Description: Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention #2: Control Group Receiving In-Person TYRO Services
Description: Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
Study: NCT06119841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expansion sphincter pharyngoplasty
Description: In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
Study: NCT05818709

Intervention type: DEVICE
Group type: OTHER
Intervention: HAC 22L
Description: Subcutaneous and/or Supraperiosteal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAC 22L
Description: Subcutaneous and/or Supraperiosteal injection
Study: NCT05852041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo MRI/PET prostate biopsy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Decipher Prostate Cancer Test
Description: Undergo decipher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotufolastat F-18 Gallium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study: NCT05785195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Generation and Delivery System
Description: The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
Study: NCT06063005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Translocation ILM Flap
Description: After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
Study: NCT06043297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eliquis 5 mg
Description: Each film-coated tablet contains 5 mg apixaban
Study: NCT06063005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM Peeling
Description: After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
Study: NCT04800796

Intervention type: OTHER
Intervention: Audiovisual
Description: Receive blended learning before and reading the Standard operating procedure
Study: NCT05292300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cornelian Cherry (Cornus mas L.)
Description: Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cornelian Cherry (Cornus mas L.)
Description: Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician.
Study: NCT05828927

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Eco-mapping tool
Description: The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caregiver-coach study visits
Description: Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
Study: NCT04550377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The drug product to be used in this study is an oral formulation of CBD
Study: NCT05100537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuing a routine life
Description: No intervention will be made in the control group.
Study: NCT04653493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR engineered autologous T-cells
Description: Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study: NCT06177366

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples will be collected at diagnosis, in the same time as BOM is performed
Study: NCT04856137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Paclitaxel Ruxolitinib
Description: Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
Study: NCT06213662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A for injection
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study: NCT05157126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Liquid gentamicin administered at the open fracture site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Normal saline administered at the open fracture site
Study: NCT05535647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and HAIC
Description: Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
Study: NCT05359393

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a combination therapy including tislelizumab
Description: Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v).
Study: NCT05996510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
Study: NCT04550377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The drug product to be used in this study is an oral formulation of CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active medication
Study: NCT06077526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P.E.A.K. Rx
Description: Pain Education + Physical Activity Group Based Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive the community hospital's usual care.
Study: NCT05729061

Intervention type: DEVICE
Group type: OTHER
Intervention: Assist-Knee
Description: Investigational prosthetic knee-ankle device

Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Knee
Description: Commercially available prosthetic knee devices

Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Ankle
Description: Commercially available prosthetic ankle devices

Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Foot
Description: Commercially available prosthetic foot devices
Study: NCT05938738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-buddy
Description: PEP-buddy